UPS pushes into healthcare logistics: The company is renting out custom lab space near its main global air hub. Diagnostics companies will be able to consolidate their shipping operations and drive downstream cost-savings.

Withings unveils AI-enabled smart mirror at CES: But consumers’ low interest in prior smart mirror products isn't likely to change.

Some health systems expand local pharmacy services: But it’s not enough to fill gaps created by thousands of drugstore closings. We expect more consumers to explore alternative pharmacy offerings in 2025.

Americans blame health insurers for UHC CEO assassination: Now more than ever, healthcare marketers, PR professionals, and industry leaders need to be transparent about why healthcare costs are so high, while offering realistic solutions to drive change.

Households with GLP-1 users slash their spending on groceries: Food companies need to adapt to the shifting buying patterns of consumers on GLP-1s to stay competitive.

Consumers don’t want to pay for patient portal messages: And responding to messages takes up physicians’ ever-limited time. Here’s how AI chatbots could benefit both parties.

Drugmakers plan price hikes on over 250 branded medications in US: Facing a hit under the Inflation Reduction Act, they’re taking matters into their own hands to offset lost revenue.

US consumers see weight loss drugs as more effective than diet, exercise: Many plan to take a GLP-1 in 2025. Marketers in the health, wellness, and fitness spaces must pounce on the opportunity to frame their offerings as a better long-term bet than weight loss drugs.

Dexcom launches genAI platform: Integrating its over-the-counter continuous glucose monitor with genAI is likely a test-case to work out any kinks before a wider rollout to those using its legacy products.

Health systems partner with wellness brands for digital advertising: We explore how legacy healthcare providers are offering health and wellness brands ad placements on their digital platforms to drive revenue and connect patients with medical products and services.

Trump plans to “knock out” pharma’s middlemen: His comments sent shares of the three largest pharmacy benefit managers down in a sign of what’s to come under the incoming administration.

Amazon’s biggest healthcare moves in 2024: Amazon has prioritized connecting Prime members with healthcare and pharmacy services. We examine which of its health-focused developments could be most impactful.

CVS’ biggest healthcare moves in 2024: Eyeing a return to profitability for Aetna, the company prioritized cost-cutting measures and new leadership. We examine which of its health-focused moves could ultimately have the biggest impact on its bottom line.

Patients have mixed opinions of healthcare tech: Healthcare organizations and marketers will need to keep innovating without compromising the patient experience.

Consumers struggle to stick with healthy behaviors: There’s a disconnect between intent and behavior as consumers work to incorporate healthier habits into their daily routines. We discuss the opportunity for health marketers to close this gap.

Healthcare and pharma companies will lean further into D2C in 2025: They’re cutting out health insurers and PBMs that bottleneck patient access to their products and services. But the industry’s push into D2C won’t be met without challenges.

Digital health funding deal size steadied over the last two quarters: But with investors continuing to lean into a cautious spending approach, we expect startups’ funding woes to persist into 2025.

Many Vermonters can’t afford or access healthcare, even though most are insured: The issue isn’t lack of insurance, but rather underinsurance. We highlight this growing problem plaguing consumers across the US.

The data: Nurses remain skeptical of the impact that AI will have in healthcare settings, according to Jarrard’s 2024 Nurse Survey Report. Some 837 US nurses were surveyed in September 2024.

The battle between Big Pharma and D2C weight loss drug sellers will intensify in 2025: We explore the competitive GLP-1 drug market and detail what’s at stake for drugmakers and D2C companies selling compounded weight loss medications.